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Abstract
Background: Immunoglobulin light chains are classified as middle molecule uremic toxins able to interact with B
lymphocyte membranes leading to the activation of transmembrane signaling. The ensuing impairment of
neutrophil function can contribute to the chronic inflammation state of uremic patients, and the increased risk of
bacterial infections or vascular calcifications. The aim of this crossover observational study was to assess the
difference in free light chain removal by three different hemodialysis filters in patients not affected by multiple
myeloma.
Methods: Free light chain removal was compared in the polymethylmethacrylate (PMMA) membrane Filtryzer BK-F,
the polyphenylene HFR17 filter and the conventional polysulfone filter F7HPS. Twenty chronic hemodialysis patients
were enrolled: mean age was 67.7 ± 17.0 years, M/F = 14/6, dialysis vintage (months) 25.5 ± 32.0. The patients were
randomized into two groups of treatment lasting 6 weeks each. The dialysis sessions checked were the midweek
sessions and the blood was drawn at times 0, 120’ and 240’. Kappa (k) and lambda (λ) light chain levels,
β2microglobulin (β2M), C reactive protein (CRP) and albumin were checked.
Results: K light chain levels were 345.0 ± 100.0 mg/L, λ light chains were 121.4 ± 27.0 mg/L. The values of k light
chains at times 120’ and 240’ were significantly lower with PMMA and HFR17 than those obtained with F7. The
reduction ratio per session (RRs) for k light chains was 44.1 ± 4.3% with HFR17, 55.3 ± 3.4% with PMMA, 25.7 ± 8.3%
with F7 (p = 0.018). The RRs for λ light chains was 30.3 ± 2.9% with HFR17, 37.8 ± 17.3% with PMMA, 14.0 ± 3.9%
with F7 (p = 0.032). As to β2M, RRs was 42.4 ± 3.2% with HFR17 vs. 33.9 ± 2.8% with PMMA vs. 6.3 ± 1.9% with
F7 (p = 0.022). The three filters tested showed no differences in CRP or albumin levels.
Conclusion: In terms of light chain and β2M removal, the PMMA and on-line HFR filters are similar and both
are significantly more effective than the F7 filter in chronic dialysis patients.
Trial registration: The present trial was registered retrospectively (NCT02950389, 31/10/2016).
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Background
Immunoglobulin light chains are classified as middle
molecule uremic toxins together with β2M and parathy-
roid hormone [1]. They have a mean molecular weight
of 25,000 daltons for monomers (k free light chains) and
approximately 50,000 daltons for dimers (λ free light
chains) [1].
Raised serum levels of polyclonal free light chains can
impair neutrophil function in terms of: 1) inhibited
chemotactic movement; 2) reduced activation of glucose
uptake; 3) inhibited apoptosis [2].
Immunoglobulin light chains are able to interact with
B lymphocyte membranes leading to the activation of
transmembrane signaling [2]. The ensuing impairment
of neutrophil function can contribute to the chronic in-
flammation state of uremic patients and to the increased
risk of bacterial infections [2]. Desjardins et al. demon-
strated an association between free light chain levels and
vascular calcification progression in chronic kidney dis-
ease patients [3]. Nonetheless, serum free light chains in
patients with chronic kidney disease are associated with
the risk of end stage renal disease and death [4].
It seems that high flux PMMA membranes signifi-
cantly reduce the light chain level, presumably due to
adsorption [5]. This behavior has led to the use of
PMMA in the removal of monoclonal free light chains
during multiple myeloma [6].
Preliminary reports describe a significant reduction in
free light chains also during hemodiafiltration with rein-
fusion of endogenous ultrafiltrate (on-line HFR) [7]. A
recent paper by Borrelli et al. reported an improvement
in chronic inflammation after chronic online HFR in dia-
lysis patients [8].
The aim of this crossover observational study was to
compare free light chain removal by three different
hemodialysis filters in a cohort of chronic dialysis pa-
tients not affected by multiple myeloma.
Methods
One hundred and sixty-three patients on chronic
hemodialysis at the Nephrology, Dialysis and Trans-
plantation Unit of S.Orsola University Hospital in Bol-
ogna were considered for the study. The patients were
enrolled between November 2013 and March 2015.
The inclusion criteria were free light chain values
>100 mg/L for k chains and >50 mg/L for λ chains.
These levels were chosen arbitrarily because no cut-off
levels are available in the literature for the assessment of
lowered serum free light chain values during
hemodialysis in patients with end-stage renal disease.
Fifty-five patients who had light chain levels higher than
those required by the inclusion criteria were selected.
Among these, 35 patients were excluded: 21 for intradia-
lytic hypotension during bicarbonate dialysis, six patients
for multiple myeloma requiring the double PMMA filter
application, five for poly-allergy, one for transferral to a
peripheral dialysis facility, one for recovery of renal function
and one for HIV positivity. Other inclusion criteria were:
age >18 years, absence or <200 ml/die residual diuresis, fis-
tula or central venous catheter with blood flow >250 ml/
min. Finally 20 patients were enrolled. Patient characteris-
tics are summarized in Table 1. The filters used during the
study were: i) HFR17 (Bellco, Mirandola, Italy), a double
chamber filter used for online HFR. The first part of the fil-
ter consisted in a polyphenylene high flux hemofilter with
an ultrafiltration coefficient (Kuf) of 28 ml/h/mmHg, a sur-
face area of 0.7 m2 and a membrane cut-off value of 35,000
daltons. The endogenous ultrafiltrate rate is obtained auto-
matically by means of the transmembrane pressure levels in
the hemofilter. These are calculated from two pressure sen-
sors: the first is on the arterial bubble chamber and the sec-
ond before the roller pump of the ultrafiltrate. The
ultrafiltrate is driven from this hemofilter to a 40 g neutral
styrenic resin that allows an adsorbing area of 28,000 m2.
After adsorption, the ultrafiltrate is added to the whole
blood that, in turn, passes into the second HFR17 filter, a
polyphenylene low flux filter (Kuf 13 ml/h/mmHg, surface
area 1.7 m2) where the weight loss and diffusive depuration
take place. ii) PMMA (Toray Filtryzer BK-F, Tokyo, Japan)
with a surface area of 2.1 m2, a membrane cut-off value of
20,000 daltons and an ultrafiltration coefficient (Kuf) of
26 ml/h/mmHg. iii) A conventional polysulfone membrane
(Fresenius F7HPS, Bad Homburg, Germany) with a cut-off
of 11,500 daltons, a Kuf of 16 ml/h/mmHg and a surface
area of 1.7 m2 was used as a control dialyzer.
Table 1 Characteristics of the patients enrolled
Group A Group B
Age (years) 64.2 ± 16.0 69.8 ± 14.5
Gender (M/F) 7/3 6/4
Dialysis vintage (months) 24.5 ± 30.3 27.2 ± 33.2
Type of dialysis (HD/HDF) 6/4 7/3
Vascular access (CVC/AVF) 8/2 7/3
Kappa light chains (mg/L) 341.3 ± 97.1 353.4 ± 115.5
Lambda light chains (mg/L) 120.8 ± 25.3 124.7 ± 26.2
Serum proteins (g/dl) 5.9 ± 1.1 6.4 ± 0.7
Serum albumin (g/dl) 3.6 ± 0.3 3.5 ± 0.7
Causes of end stage renal disease
- Nephroangiosclerosis





- Type 1 diabetes
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The patients enrolled were randomized into two
groups of treatments lasting 6 weeks each (Fig. 1).
Group A: 1st and 2nd weeks with bicarbonate dialysis
and filter PMMA, 3rd and 4th weeks with filter HFR17,
5th and 6th weeks with bicarbonate dialysis filter F7.
Group B: 1st and 2nd weeks with filter HFR17, 3rd and
4th weeks with bicarbonate dialysis and filter PMMA,
5th and 6th weeks with bicarbonate dialysis filter F7
(Fig. 2). The dialysis sessions carried out during weeks 1,
3 and 5 were considered washout sessions between
weeks 2, 4 and 6 when the assessment of λ and k light
chains, β2M, C reactive protein and albumin was sched-
uled. Week number 1 was the washout period between
the usual dialytic treatment of the patients enrolled and
the beginning of the study. The checking dialysis session
was the midweek session and the blood was drawn on
starting dialysis (time 0), at two hours (time 120’) and at
dialysis end (time 240’). All the dialysis sessions lasted
four hours. Mean blood flow was 310 ± 30 ml/min, the
mean ultrafiltration rate was 700 ± 200 ml/h, during
HFR the endogenous ultrafiltrate rate was 2.3 ± 0.4 ml/h.
Dialysate flow was 500 ml/min. Low molecular weight
heparin enoxaparin (Clexane®, Sanofi, Milan Italy) was
used for anticoagulation of the extracorporeal circuit.
Doses of 2000 IU (patients <50 kg of body weight),
4000 IU (patients between 50 to 90 kg of body weight)
or 6000 IU (patients >90 kg of body weight) were ad-
ministered in a single bolus on starting dialysis. Frese-
nius 5008 and Bellco Flexya dialysis machines were used.
The concentrations of k and λ light chains and β2M
were measured by nephelometry (kit Freelite k/lambda,
The Binding Site Group Ltd., Birmingham, UK;
IIMAGE/IMMAGE 800 Beckman Coulter instrument,
Brea California USA, Beckman Coulter β2M kit).
Normal values: k light chains 3.3 -19.9 mg/L, λ light
chains 5.7–26.3 mg/L, β2M 0.7–2 mg/L. Molecular
weights: k light chains: 22,500 daltons; λ light chains:
45,000 daltons; β2M: 11,818 daltons. The reference
range for patients with normal kidney function was
considered between 0.26 and 1.65 according to Bour-
guignon et al. [9]. CRP concentration was measured
by turbidimetry (CRPLX, Tina-quant C-Reactive-
Protein; Roche/Hitachi 902 analyzer). CRP normal
value < 0.8 mg/dl, molecular weight 120,000 daltons.
Albumin was assessed using the common laboratory
method. The reduction rate per session (RRs) was cal-
culated as follows [10]:
RRs ¼ Cpre− Cpost‐corr
 
= Cpre  100 ð1Þ
where Cpre is the predialysis solute level, and Cpost-corr is
the post-dialysis solute concentration. The values mea-
sured during dialysis were corrected for hemoconcentra-
tion due to the patient’s weight loss assuming a
unicompartimental behavior of light chains described by
the following formula [11]:
Cpost−corr ¼ Cpost= 1þ ΔBW= 0:2 BWpost
   
ð2Þ
where Cpost-corr is the post-dialysis solute concentration
and Cpost-corr is the concentration of light chains cor-
rected for the hemoconcentration, ΔBW is the weight
subtracted during dialysis, and BW is the body weight at
the end of dialysis.
Statistical analyses
Statistical analysis was performed using SPSS statistical
software. The data are presented as mean ± standard
error of the mean. The Shapiro-Wilk test, suitable for
small populations, showed a non-normal distribution of
the variables, for which the non-parametric Friedman
test was used. The p value <0.05 was considered normal.
The Wilcoxon Signed Rank Test was subsequently used
to see which pairwise comparisons resulted statistically
different. In addition, as a multiple comparison was
done, we applied the Bonferroni correction, thereby set-
ting a p value = 0.05 / 3 = 0.0167. For each of the sam-
pling times 0.120 and 240 min, we compared the results
and the RRs obtained with the different filters (HFR17,
PMMA, F7).
Results
HFR17 removal of free light chains was statistically signifi-
cant between time 0’ (k: 361.6 ± 100.7 mg/L; λ 122.4 ±
27.6 mg/L) and time 120’ (k: 233.6 ± 68.8 mg/L; λ 84.3 ±
15.6 mg/L) for both k and λ chains (p <0.001). K and λ
chain concentrations were reduced between times 120’
and 240’ but the value did not reach statistical significance
(p = ns). HFR17 significantly reduced β2M values between
time 0’ (38.4 ± 6.0 mg/L) and time 120’ (23.9 ± 3.6 mg/L)
Fig. 1 Study design
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and between times 120’ and 240’ (at time 240’ β2M values
were 21.6 ± 4.1 mg/L) (p = 0.04). CRP values did not ex-
hibit statistically significant changes at the three times
considered.
PMMA significantly reduced k and λ chains between
time 0’ (k: 429.4 ± 110.3 mg/L; λ: 120.1 ± 19.9 mg/L) and
time 120’ (k: 218.5 ± 62.2 mg/L; λ: 72.2 ± 14.3 mg/L)
(p < 0.001), but no significant reduction was found (p = ns)
between time 120’ and time 240’. A significant reduction
was found for β2M between time 0’ (39.3 ± 5.4 mg/L) and
time 120’ (27.3 ± 4.0 mg/L) (p < 0.001), but not between
times 120’ and 240’ (p = ns).
The values obtained for the k light chains with the F7
filter showed a non-significant reduction during each
time interval considered; the same behavior was found
for λ chains and β2M values.
By comparing the different filters used at the different
checking times the following results were obtained
(Fig. 2): k light chains levels at time 0’ did not differ
among the three filters tested (p = ns). At time 120’ the
three filters differed significantly with the PMMA filter
showing the lowest value (p < 0.05). At time 240’ the k
light chains level were significantly lower with HFR17
and PMMA in comparison to F7 (p < 0.05) (Fig. 2). No
difference in λ light chain levels was found among the
three filters tested at times 0’, 120’ and 240’ (Fig. 3). B2M
levels at time 0’ did not differ among the three filters
tested. At time 120’, β2M levels were lower with HFR17
Fig. 2 k free light chain removal with the three dialyzers tested at times 120’ PMMA = HFR17 < F7HPS and 240’ PMMA = HFR17 < F7HPS
Fig. 3 λ free light chain removal with the three dialyzers tested: no differences were found at the checking times considered
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and PMMA in comparison with F7 (p < 0.001) and at
240’ (p < 0.001) when HFR17β2M levels seemed slightly
lower than those of PMMA (Fig. 4). CRP values at times
0’, 120’ and 240’ did not differ among the three filters
tested (Fig. 5).
Finally the RRs was measured for k and λ light chains
and β2M. For k light chains, RRs values were higher
with HFR17 and with PMMA than those obtained with
F7 (p = 0.018). RRs of λ light chains and of β2M showed
the same behavior (p = 0.032 and p = 0.022 respectively)
(Fig. 6).
Predialysis and postdialysis k/λ ratio values with the
three dialyzers tested are showed in Table 2 and Fig. 7.
After dialysis, the frequency of patients with a k/λ ratio
in the normal range described for subjects with normal
kidney function was 60% (12/20) with HFR17, 55% (11/
20) with PMMA and 40%(8/20) with F7 (p = ns).
There was no difference in albumin levels among the
three dialyzers tested. Using HFR17 albumin was 3.6 ±
0.4 g/dl on starting dialysis vs. 3.7 ± 0.7 at dialysis end
(p = ns). With PMMA albumin values on starting dialysis
were 3.6 ± 0.4 g/dl vs. 3.6 ± 0.7 g/dl at dialysis end
(p = ns). Using the F7HPS dialyzer albumin was 3.6 ±
0.4 g/dl on starting dialysis vs. 3.7 ± 0.6 g/dl at dialysis end
(p = ns). No difference among the three dialyzers was
found comparing the values obtained with each filter at
the checking times considered in the study.
Spearman’s correlation test was used to evaluate any
correlation between the blood flow rate during the single
dialysis session and the k and λ free chain concentration.
The correlation coefficient for the PMMA dialyzer at
120’ was 0.056 (p = ns) for k light chains, -0.272 (p = ns)
for λ light chains. At dialysis end it was -0.161 (p = ns)
for k light chains and -0.131 (p = ns) for λ light chains.
The correlation coefficient for HFR17 at 120’ was -0.483
(p = ns) for k light chains, -0.268 (p = ns) for λ light
chains. At dialysis end it was -0.161 (p = ns) for k light
chains and -0.075 (p = ns) for λ light chains.
Discussion
The present study showed that the k light chains were
significantly lower with HFR17 and PMMA dialyzers
than with the F7 during a four-hour dialysis treatment.
Free light chain removal had already approached a plat-
eau at the second hour of dialysis with both PMMA and
HFR17 filters. For both PMMA and HFR17 no further
significant improvement in k and λ light chains was
found in the second part of the dialysis sessions. The
RRs showed free k light chain removal was higher with
PMMA than with the HFR17 or F7 dialyzers. λ light
chain removal peaked after two hours of dialysis treat-
ment but without statistical differences among the three
filters. This is probably explained by the small cohort of
patients enrolled and by the low levels of λ light chains
considered suitable for the study at dialysis start. λ free
light chain removal seems to be more difficult due to
the dimeric structure and higher molecular weight than
k light chains [12]. Nonetheless, PMMA showed signifi-
cantly higher RRs for λ free light chains than the HFR17
and F7 dialyzers. β2M removal at the second hour of
treatment was already significantly lower with both
HFR17 and PMMA than with the F7 dialyzer. The β2M
RRs was significantly higher with both online HFR and
PMMA in comparison with F7.
Many studies have sought to establish the optimal dialy-
sis technique for free light chain removal during multiple
myeloma with renal involvement. However, the issue of
free light chains as uremic toxins in non-multiple mye-
loma patients has received only marginal attention [2]. In
the field of free light chain removal the PMMA membrane
is the first choice technique since this membrane removes
proteins not only via permeation but also via an adsorptive
Fig. 4 β2M removal with the three dialyzers tested at times 120’ PMMA = HFR17 < F7HPS and 240’ PMMA = HFR17 < F7HPS
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mechanism [5]. In 2002, Cohen enrolled 71 non-myeloma
chronic hemodialysis patients treated with bicarbonate
dialysis and 33 patients treated with hemodiafiltration
[13]. He tested free light chain removal by six different di-
alyzers in the group of patients treated with bicarbonate
dialysis, and three dialyzers in the group of patients who
underwent hemodiafiltration. Free light chains, namely λ
free light chains, were significantly reduced only with the
PMMA dialyzer. The removal rate considered two hours
after dialysis start was 43% for λ free light chains and 12%
for the k free light chains. Unfortunately only four patients
underwent PMMA hemodialysis while four patients
underwent PMMA hemodiafiltration [13]. Fabbrini et al.
carried out a retrospective study on ten acute and chronic
dialysis patients with high free light chain levels (k or λ >
500 mg/dl). Five patients underwent bicarbonate dialysis
with a single PMMA filter and the other five patients with
the “enhancing adsorption properties technique” (EAD)
[14]. With EAD the PMMA dialyzer is replaced after two
hours of dialysis treatment. The five single PMMA filter
patients showed free light chain RRs corresponding to
22.3% for k light chains and 21% for λ light chains after
four hours of treatment. The five patients who underwent
EAD showed RRs of 31% for k free light chains and 53.1%
for λ free light chains [14].
Testa et al. enrolled 11 chronic hemodialysis patients
undergoing online HFR, finding a significant reduction
of k and λ free light chains with the HFR17 dialyzer. The
mean reduction of k light chains was 30% and 20% for λ
free light chains [7]. The removal of free light chains
during online HFR depends on the adsorption obtained
by the resin cartridge of the HFR17 filter. This was con-
firmed by an in vitro experiment where 10 ml of styrenic
neutral resin were incubated with the serum of patients
Fig. 5 CRP values with the three dialyzers tested at the checking times considered
Fig. 6 Comparison of the RRs obtained with the three dialyzers tested for k and λ light chains and for β2M. PMMA = HFR17 > F7HPS
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with IgA-k and IgG-k multiple myeloma. The serum
monoclonal protein was significantly reduced, but unfor-
tunately their study did not include a control group [7].
A conventional polysulfone membrane like the F7
seems to allow some removal of free light chains by ad-
sorption because its cut-off is about 11,000 daltons and
it does not allow free light chain removal by diffusion or
convection. Birk et al. observed that one type of polysul-
fone (Fresenius F60) showed a higher adsorption of both
total proteins and low molecular weight proteins than
another polysulfone membrane tested (D30) during an
“in vitro” comparison of 11 different membrane mate-
rials [15]. Interestingly, Lamy et al. enrolled 31 chronic
hemodialysis patients in a prospective observational
study evaluating the reduction of free light chain values
with high-flux dialyzers like FX80 and FX100 [15]. The
RRs for k free light chains was 66% with online HDF vs.
52% with bicarbonate dialysis (p < 0.001), whereas no dif-
ference was found between the two techniques tested for
λ free light chains (37% RRs with both techniques) [16].
Our study found no differences in CRP levels among
the three dialyzers tested. CRP is considered a marker of
intradialytic inflammatory activation and selective solute
removal by the dialyzers tested [17]. Another important
issue during light chain removal is the albumin loss: fil-
ters with a high cut-off allow an albumin loss that can
approach 63 g/session [18]. No albumin loss was found
during each session with the three dialyzers tested con-
firming the selectivity of the adsorption. This was due to
the low cut-off value of the PMMA and F7 dialyzers and
to reinfusion of the endogenous ultrafiltrate after ad-
sorption obtained with the neutral resin of the HFR17
dialyzer into the whole blood returned to the patient.
The main weaknesses of this study are the small co-
hort of patients enrolled, the low levels of λ light chains
considered suitable for the study at dialysis start and the
limited number of biomarkers considered. Conversely,
one of the strengths of the study is its crossover study
design, which allows each patient to be his/ her control,
strongly reducing the variability among patients. Other
strengths are the randomization of the patients into two
groups and the washout periods between the experimental
phases with each filter tested, reducing the carryover effect
of the previous filter / hemodialysis technique used.
Conclusions
Our study yielded some important results for everyday
clinical practice. Firstly, the routine use of PMMA and
HFR17 filters can significantly reduce the burden of free
light chains and β2M in chronic dialysis patients not af-
fected by multiple myeloma. PMMA was more effective
in removing free light chains, while HFR17 proved more
effective in the removal of β2M [19]. Secondly, this effi-
cacy allows the chronic use of the two dialyzers in
chronic dialysis patients when the recovery of multiple
myeloma is obtained but not the recovery of renal fail-
ure. In this case, use of two PMMA filters for each
Table 2 Ratio k/l light chains before (time 0) and after dialysis
(time 240’)
HFR 17 PMMA F7 P
Ratio k/l light chains
-time 0 7.7 ± 4.2 8.9 ± 4.7 10.6 ± 6.1 ns
-time 240’ 4.8 ± 2.2 6.8 ± 3.6 14.3 ± 10.4 0.02
0.02 <0.001 ns
Fig. 7 Effect of dialysis with HFR17, PMMA and F7 on k/λ ratio before dialysis (time 0’) and after dialysis (time 240’). Dashed lines = normal
reference range. Continuous lines = extended renal failure reference range [9]
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dialysis session or use of the HFR-Supra is not indicated
because of the low light chain values [20, 21]. Thirdly,
the polysulfone membrane showed a surprising intrinsic
adsorptive ability, recently improved by the technical
evolution of this membrane as in the case of polye-
thersulfone and polyester polymer alloy membrane fil-
ters [9, 22]. The depurative efficiency of the dialyzers
tested on the middle molecules considered should en-
courage new studies with more patients to confirm
these results on a large number of uremic toxins in
the middle molecule range.
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